Список літератури, використаний в процесі адаптації клінічної настанови

1.Management of Acute Myocardial Infarction in patients presenting with ST-segment elevation. ESC Clinical Practice Guidelines 2012

2.Guidelines for Myocardial Revascularisation. ESC Clinical Practice Guidelines 2010

3.Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease. 2011, ACCF/AHA

4.Antithrombotic therapy for non–ST-segment elevation acute coronary syndromes. ACCP evidence-based clinical practice guidelines (8th edition), Jun 01, 2008 United States

5.Guideline for Coronary Artery Bypass Graft Surgery. 2011, ACCF/AHA

6.Guideline for Percutaneous Coronary Intervention. 2011, ACCF/AHA/SCAI

7.Third Universal Definition of Myocardial. ESC Clinical Practice Guidelines 2012

8.Held С., Å senblad N., Bassand J.P., et al. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery //J Am Coll Cardiol. 2011; 57(6): 672-684

9.Varenhorst C., Alströ m U., Scirica B.M. et al. Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery // J Am Coll Cardiol. 2012; 60(17): 1623-1630

10. Bellamy GR, Rasmussen HH, Nasser FN, Wiseman JC, Cooper RA.Value of two-dimensional echocardiography, electrocardiography, and clinical signs in detecting right ventricular infarction. Am Heart J. 1986 Aug; 112(2): 304-9.

11. Keeley EC, Hillis LD: Left ventricular mural thrombus after acute myocardial infarction. Clin Cardiol 1996, 19(2): 83-86

12. Rehan A, Kanwar M, Rosman H, et al. Incidence of post myocardial infarction left ventricular thrombus formation in the era of primary percutaneous intervention and glycoprotein IIb/IIIa inhibitors. A prospective observational study. Cardiovascular Ultrasound 2006, 4: 20

13. Keeley EC, Hillis LD: Left ventricular mural thrombus after acute myocardial infarction. Clin Cardiol 1996, 19(2): 83-86

14. Chatterjee S., Chaudhuri D., Vedanthan R., et al. Early intravenous beta-blockers in patients with acute coronary syndrome–A meta-analysis of randomized trials // International Journal of Cardiology – 2012 – in press.

15. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo–controlled trial Lancet 2005; 366: 1622–32

16. Goldberger JJ, Bonow RO, Cuffe M, et al. Beta-blocker Use Following Myocardial Infarction: Low Prevalence of Evidence-based Dosing //Am Heart J. 2010 September; 160(3): 435–442

17. Goldberger J, Bonow R, Cuffe M, et al. Post-myocardial infarction beta-blocker therapy: the bradycardia conundrum. Rationale and design for the Pacemaker & beta-blocker therapy post-MI (PACE-MI) trial. Am Heart J. 2008; 155(3): 455–64.

18. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011 Dec; 32(23): 2999-3054.

19. Lenderink T, Boersma E, Gitt AK, Zeymer U, Wallentin L, Van de Werf F, Hasdai D, Behar S, Simoons ML. Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes. Eur Heart J. 2006 Aug; 27(15): 1799-804.

20. Heeschen C, Hamm CW, Laufs U, Bö hm M, Snapinn S, White HD. Withdrawal of statins in patients with acute coronary syndromes. Circulation 2003; 107: E27.

21. Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, French WJ; National Registry of Myocardial Infarction 4 Investigators. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol. 2005 Sep 1; 96(5): 611-6.

22. McCullough P.A., Adam A., Becker C.R. et al. (2006) Risk prediction of contrast-induced nephropathy. Am. J. Cardiol., 98(6A): 27–36K.

23. Berns A.S. (1989) Nephrotoxicity of contrast media. Kidney Int., 36(4): 730–740.

24. Guitterez N.V., Diaz A., Timmis G.C. et al. (2002) Determinants of serum creatinine trajectory in acute contrast nephropathy. J. Interv. Cardiol., 15(5): 349–354.

25. Cockcroft D.W., Gault M.H. (1976) Prediction of creatinine clearance from serum creatinine. Nephron, 16(1): 31–41.

26. Rosovsky M.A., Rusinek H., Berenstein A. et al. (1996) High-dose administration of nonionic contrast media: a retrospective review. Radiology, 200(l): 119–122.

27. Kini A.S., Mitre C.A., Kim M. et al. (2002) A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam. Catheter Cardiovasc. Interv., 55(2): 169–173.

28. Mehran R., Nikolsky E. (2006) Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int. Suppl., (100): S11–15.